Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Gerritsen

Showing results (191-200 of 224) with videos related to

Pageof 23
Sort By:
Frontiers in Nuclear Medicine|October 2, 2024
An Update to the Pilot Study of <sup>177</sup>Lu-PSMA in Low Volume Hormone-Sensitive Prostate CancerBastiaan M Privé, Constantijn H J Muselaers, Inge M van Oort, et al.
Oncoimmunology|July 8, 2022
Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtypeSandra van Wilpe, Donjetë Simnica, Peter Slootbeek, et al.
Prostate Cancer and Prostatic Diseases|October 12, 2022
Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registryGijs P A van den Bergh, Malou C P Kuppen, Hans M Westgeest, et al.
Targeted Oncology|September 28, 2018
Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and ExemestaneAnnelieke E C A B Willemsen, Lioe-Fee de Geus-Oei, Maaike de Boer, et al.
Prostate Cancer and Prostatic Diseases|March 22, 2021
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world populationH M Westgeest, M C P Kuppen, A J M van den Eertwegh, et al.
Prostate Cancer and Prostatic Diseases|July 8, 2022
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapyMaarten J van der Doelen, Irma M Oving, Dirk N J Wyndaele, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 29, 2024
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of <sup>223</sup>Ra Therapy in Metastatic Castration-Resistant Prostate Cancer PatientsDianne Bosch, Kim J M van der Velden, Irma M Oving, et al.
Clinical Genitourinary Cancer|December 1, 2021
Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the NetherlandsMalou C P Kuppen, Hans M Westgeest, Alfons J M van den Eertwegh, et al.
European Urology|August 20, 2020
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term SurvivorsKarim Fizazi, Charles G Drake, Tomasz M Beer, et al.
Prostate Cancer and Prostatic Diseases|July 13, 2021
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancerBastiaan M Privé, Peter H J Slootbeek, Babette I Laarhuis, et al.
Pageof 23

Showing results (191-200 of 224) with videos related to

Sort By:
Pageof 23
Frontiers in Nuclear Medicine|October 2, 2024
An Update to the Pilot Study of <sup>177</sup>Lu-PSMA in Low Volume Hormone-Sensitive Prostate CancerBastiaan M Privé, Constantijn H J Muselaers, Inge M van Oort, et al.
Oncoimmunology|July 8, 2022
Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtypeSandra van Wilpe, Donjetë Simnica, Peter Slootbeek, et al.
Prostate Cancer and Prostatic Diseases|October 12, 2022
Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registryGijs P A van den Bergh, Malou C P Kuppen, Hans M Westgeest, et al.
Targeted Oncology|September 28, 2018
Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and ExemestaneAnnelieke E C A B Willemsen, Lioe-Fee de Geus-Oei, Maaike de Boer, et al.
Prostate Cancer and Prostatic Diseases|March 22, 2021
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world populationH M Westgeest, M C P Kuppen, A J M van den Eertwegh, et al.
Prostate Cancer and Prostatic Diseases|July 8, 2022
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapyMaarten J van der Doelen, Irma M Oving, Dirk N J Wyndaele, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 29, 2024
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of <sup>223</sup>Ra Therapy in Metastatic Castration-Resistant Prostate Cancer PatientsDianne Bosch, Kim J M van der Velden, Irma M Oving, et al.
Clinical Genitourinary Cancer|December 1, 2021
Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the NetherlandsMalou C P Kuppen, Hans M Westgeest, Alfons J M van den Eertwegh, et al.
European Urology|August 20, 2020
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term SurvivorsKarim Fizazi, Charles G Drake, Tomasz M Beer, et al.
Prostate Cancer and Prostatic Diseases|July 13, 2021
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancerBastiaan M Privé, Peter H J Slootbeek, Babette I Laarhuis, et al.
Pageof 23